Crossref

1. Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review

- Peter Wigfield

- Urbano Sbarigia

- Mahmoud Hashim

- Talitha Vincken

- Bart Heeg

2. QALY league table of Iran: a practical method for better resource allocation

- Reza Hashempour

- Behzad Raei

- Majid Safaei Lari

- Nasrin Abolhasanbeigi Gallezan

- Ali AkbariSari

3. Cost-Effectiveness Analysis of Pharmacogenomics-Guided Versus Standard Dosing of Warfarin in Patients with Mechanical Prosthetic Heart Valve

- Homa Hemati

- Marzieh Nosrati

- Mandana Hasanzad

- Parham Rahmani

- Soroush Fariman

- Mohadese Sarabi

- Sepideh Shirvani

- Parham Sadeghipour

- Shekoufeh Nikfar

4. A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa

- Mouaddh Abdulmalik Nagi

- Pramitha Esha Nirmala Dewi

- Montarat Thavorncharoensap

- Sermsiri Sangroongruangsri

5. Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

- Mehdi Rezaee

- Mohammad Hossein Morowvat

- Maryam Poursadeghfard

- Armin Radgoudarzi

- Khosro Keshavarz

6. Cost-Effectiveness Analysis of Triptorelin, Goserelin, and Leuprolide in the Treatment of Patients With Metastatic Prostate Cancer: A Societal Perspective

- Mehdi Rezaee

- Iman Karimzadeh

- Amir Hashemi-Meshkini

- Shahryar Zeighami

- Mohammad Bazyar

- Farhad Lotfi

- Khosro Keshavarz

7. Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C

- Zahra Goudarzi

- Abdollah Poursamad

- Iman Karimzadeh

- Nahid Jallaly

- Khosro Keshavarz

- Seyed Moayed Alavian

8. Cost‐Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept

- Ahmad Gholami

- Jassem Azizpoor

- Elham Aflaki

- Mehdi Rezaee

- Khosro Keshavarz

- Mihajlo Jakovljevic